deltatrials
Terminated PHASE2 NCT00003492

Antineoplaston Therapy in Treating Patients With Stage IV Lung Cancer

Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Large Cell, Undifferentiated Or Poorly Differentiated Stage IV Carcinoma of the Lung

Sponsor: Burzynski Research Institute

Conditions Stage IV Lung Cancer
Interventions Antineoplaston therapy (Atengenal + Astugenal)
Updated 7 times since 2017 Last updated: Dec 14, 2020 Started: Apr 10, 1996 Primary completion: Dec 1, 2000 Completion: Dec 1, 2000

This PHASE2 trial investigates Stage IV Lung Cancer and is currently terminated or withdrawn. Burzynski Research Institute leads this study, which shows 7 recorded versions since 1996 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE2

  5. Dec 2017 — Jun 2018 [monthly]

    Terminated PHASE2

    Status: Unknown Status → Terminated

▶ Show 2 earlier versions

  1. Feb 2017 — Dec 2017 [monthly]

    Unknown Status PHASE2

  2. Jan 2017 — Feb 2017 [monthly]

    Unknown Status PHASE2

    First recorded

Apr 1996

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Burzynski Research Institute
Data source: Burzynski Research Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Houston, United States